Abstract
Which signaling pathway and protein to select to mitigate the patient’s expected drug resistance? The number of possibilities facing the physician is massive, and the drug combination should fit the patient status. Here, we briefly review current approaches and data and map an innovative patient-specific strategy to forecast drug resistance targets that centers on parallel (or redundant) proliferation pathways in specialized cells. It considers the availability of each protein in each pathway in the specific cell, its activating mutations, and the chromatin accessibility of its encoding gene. The construction of the resulting Proliferation Pathway Network Atlas will harness the emerging exascale computing and advanced artificial intelligence (AI) methods for therapeutic development. Merging the resulting set of targets, pathways, and proteins, with current strategies will augment the choice for the attending physicians to thwart resistance.
| Original language | English |
|---|---|
| Article number | 3 |
| Journal | Signal Transduction and Targeted Therapy |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| State | Published - 6 Jan 2021 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020, The Author(s).
Funding
This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported [in part] by the Intramural Research Program of NIH, National Cancer Institute, Center for Cancer Research.
| Funders | Funder number |
|---|---|
| National Institutes of Health | |
| National Cancer Institute | HHSN261200800001E, ZIABC010441 |
